Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513638 | 1.00 | SYK (0.56) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL25318929 | 1.00 | SYK (0.56) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL8607451 | 0.92 | SYK (0.55) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL19401968 | 0.91 | SYK (0.58) | SYKATMMAPTCASP1CTSS | |
| SCHEMBL19401966 | 0.91 | SYK (0.58) | SYKATMMAPTCASP1CTSS | |
| SCHEMBL3466395 | 0.89 | SYK (0.57) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL24298360 | 0.89 | SYK (0.57) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL3466396 | 0.89 | SYK (0.57) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL6685926 | 0.89 | SYK (0.59) | SYKATMKLK5KLK7PPARA | |
| SCHEMBL6685929 | 0.89 | SYK (0.59) | SYKATMKLK5KLK7PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-117362386-A | Zwitterionic polypeptide, carrier, targeted nano-drug and preparation method and application thereof | 浙江大学 | 2024-01-09 | — | — | CN | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-10233213-B2 | Foldamer helix bundle-based molecular encapsulation | UREKA SARL (FR) | 2019-03-19 | — | — | US | disclosed |
| US-20180244718-A1 | FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION | UREKA SARL (FR) | 2018-08-30 | — | — | US | disclosed |
| WO-2017037150-A1 | QUATERNARY ASSEMBLIES OF WATER-SOLUBLE NON-PEPTIDE HELICAL FOLDAMERS, THEIR USE AND PRODUCTION THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037142-A1 | FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-03-09 | — | — | WO | disclosed |
| EP-3138851-A1 | QUATERNARY ASSEMBLIES OF WATER-SOLUBLE NON-PEPTIDE HELICAL FOLDAMERS, THEIR USE AND PRODUCTION THEREOF | Centre National de la Recherche Scientifique - CNRS - (FR) | 2017-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233213-B2 | Foldamer helix bundle-based molecular encapsulation | CRYAB, BAG2, UACA | SYK 4092/4885ATM 4752/4885KLK5 3295/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | SYK 2284/4885ATM 206/4885KLK5 1021/4885 |
| US-20180244718-A1 | FOLDAMER HELIX BUNDLE-BASED MOLECULAR ENCAPSULATION | CRYAB, BAG2, UACA | SYK 4092/4885ATM 4752/4885KLK5 3295/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | SYK 2284/4885ATM 206/4885KLK5 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.